ORTC Ortec International Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ORTC Ortec International

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Lane Hall-Witt who wrote (264)	3/21/2000 11:20:00 AM
From: Lane Hall-Witt	Read Replies (1) of 272

ORTC PR -- 21 Mar 2000, 10:36 a.m. Eastern CCS Shows Superiority Over Standard of Care in Interim Analysis of Ortec's Initial Venous Ulcer Trial biz.yahoo.com Note that the treatment of venous ulcers is a $1.345 billion/year market; ORTC will apply to conduct pivotal trials for venous ulcers in the second quarter. ORTC hopes to go to market with CCS for venous ulcers in the first half of 2002. Message 12947248

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next